Inihain ni House Deputy Majority Leader Janette Garin ang House Resolution 2081 para magkasa ang House Committee on Health ng pagsisiyasat sa implementasyon ng Universal Health Care (UHC) Law.
Partikular na tututok ang pagsisiyasat sa Health Technology Assessment (HTA) process at mga proseso na nakakabalam sa napapanahong healthcare innovations, at makapaglatag ng legislative reforms upang maging accessible ang serbisyong pangkalusugan sa lahat ng Pilipino.
Kasama rin sa pinarerepaso ang HTA Council structure at function na maaaring hindi na angkop sa mandato nito.
Giit pa niya, na kailangan rebyuhin ang pagpapatupad ng UHC law na dapat aniya ay Department of Health (DOH) at hindi ang Philippine Health Insurance Corporation (PhilHealth).
“I urge the leadership of both the House and the Senate to make the amendment of UHC a priority. We must address the elephant in the room. It is vital to fortify the country’s public health system and ensure timely access to essential health interventions for Filipinos,” sabi niya.
Isa sa kaniyang pinupunto, na ang health interventions gaya ng gamot, bakuna, at medical devices ay hindi na dapat sumailalim sa Phase IV clinical study salig sa Section 34 ng UHC law.
Lalo at itinuturing nang ligtas at epektibo ang mga sumailalim na sa Phase III clinical trial.
“The requirement for Phase IV clinical trials under Section 34 of the UHC Act may result in significant delays in providing Filipinos access to cutting-edge medical innovations and treatments, effectively requiring that such interventions be extensively used in other countries for 5 to 10 years before being made available domestically,” sabi pa niya. | ulat ni Kathleen Forbes
